

**Preferred Drug List Committee
Meeting Agenda, Open Session
January 17, 2023 11:30am to 1:00pm**

Meeting Location*

*Due to COVID-19, this meeting will be held virtually. Please use the information below to join the meeting:

Computer Audio Enabled Zoom Meeting:

<https://us02web.zoom.us/j/89837419159?pwd=ZEErV0twNFZ2RVJ2K2VnYStoNFZlZ09>

Required Passcode: 424834 **Audio Dial in:** +1 312 626 6799 **US Meeting ID:** 898 3741 9159

Members of the public are required to complete a conflict of interest form if they intend to provide public comments to the Committee. To assist the operator in coordinating public comment, completed forms are due 1 week prior to the meeting (January 10, 2023). Please email the completed form to Annette.Grant@ks.gov.

Committee Members

Jessica Bates, PharmD., BCPS (Chair)
Emily Blew, PharmD.
Taylor Gill, PharmD., BCPS
Katherine Grimsley, M.D.
Robert Haneke, Pharm.D.

Megan Hedden, PharmD.
Jonathan Jacobs, MD.
Lucy Lot, M.D.
Donna Sweet, M.D.
Wayne Wallace, M.D.

KDHE-DHCF Staff

Sri Donepudi, M.D., MMM, FAAFP
Annette Grant, RPh
Victor Nguyen, Pharm.D.

Crystal Blackmon, Sr. Admin. Specialist

Gainwell Technologies Staff

Karen Kluczykowski, RPh.
Harry Vu, PharmD

Kathy Kaesewurm, RN, BSN
Debra Illions-Clark, LPN

- I. Call to Order
 1. Announcements and Introductions

- II. Review & Approval of Meeting Minutes from 07/19/2022

- III. Old Business
 1. Consent Agenda Items
 - i. PDL New Drug Placements
 - a. Dyanavel[®] XR tablets
 - b. Fylnetra[®]
 - c. Ozobax[®]

- d. Truxima®
- e. Tyvaso DPI®
- f. Venlafaxine Besylate
- g. Xelstrym™
- ii. Committee discussion/Recommendations

IV. New Business

1. New PDL Drug Classes

- i. Iron Deficiency Anemia: Feraheme®, Injectafer®, Monoferric®, Triferic® and Triferic Avnu®
 - a. Public Comment
 - b. Committee Discussion/Recommendations
- ii. Oral Non-Statins: Zetia®, Nexletol®, Nexlizet®
 - a. Public Comment
 - b. Committee Discussion/Recommendations

2. New Drugs to Existing PDL Classes

- i. Colony Stimulating Factors- Pegfilgrastim Products- *Name change to Colony Stimulating Factors - Long-Acting* -Addition of Fylnetra®, Rolvedon™, and Stimufend®
 - a. Public Comment
 - b. Committee Discussion/Recommendations
- ii. Colony Stimulating Factors- Filgrastim Products- *Name change to Colony Stimulating Factors - Short-Acting*
 - a. Public Comment
 - b. Committee Discussion/Recommendations
- iii. Immunomodulation Agents- Ankylosing Spondylitis: Xeljanz®, Xeljanz® XR
 - a. Public Comment
 - b. Committee Discussion/Recommendations
- iv. Immunomodulation Agents- Juvenile Idiopathic Arthritis (JIA): Simponi Aria®
 - a. Public Comment
 - b. Committee Discussion/Recommendations
- v. Immunomodulation Agents- Plaque Psoriasis: Cimzia®, Sotyktu®
 - a. Public Comment
 - b. Committee Discussion/Recommendations
- vi. Immunomodulation Agents- Psoriatic Arthritis: Rinvoq®, Skyrizi®, Tremfya®
 - a. Public Comment
 - b. Committee Discussion/Recommendations
- vii. Immunomodulation Agents- Adult Rheumatoid Arthritis: Riabni®
 - a. Public Comment
 - b. Committee Discussion/Recommendations
- viii. Opioids – Short Acting: Prolate® solution/tablets, Nalocet®
 - a. Public Comment
 - b. Committee Discussion/Recommendations
- ix. Pulmonary Arterial Hypertension Agents: Flolan®, Tadliq®, Veletri®
 - a. Public Comment

- b. Committee Discussion/Recommendations
- x. Sleep Agents – Scheduled - Nonbenzodiazepines: Quiviviq™
 - a. Public Comment
 - b. Committee Discussion/Recommendations
- xi. Thyroid Hormones: Ermeza™
 - a. Public Comment
 - b. Committee Discussion/Recommendations

V. Adjourn

The next PDL Committee meeting is scheduled for July 18, 2023.

****THIS AGENDA IS SUBJECT TO CHANGE****